CIK 0002130606 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Obsidian Therapeutics, Inc.
Sign in to watch- Ticker
- OBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 421977778
- Phone
- (781) 806-6245
- Business address
- 1030 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02138
- Former names
- Gazelle Parent, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 6 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Reisenauer Mark L Director | Grant or award · Stock Option (Right to Buy) | +75,364 | 75,364 | ||
| 2026-08-03 | Feder Julie B Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +164,790 | 164,790 | ||
| 2026-08-03 | Hari Parameswaran Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +331,173 | 331,173 | ||
| 2026-08-03 | Jagasia Madan Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +678,477 | 678,477 |
Page 1 of 1 · 4 trades